SCHEMBL603667

SCHEMBL603667

COC(=O)c1cc(CBr)ccc1Br

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
MAPT P10636 2/20 0.50
GAA P10253 2/20 0.50
HSD17B10 Q99714 2/20 0.50
KDM4E B2RXH2 1/20 0.50
HPGD P15428 1/20 0.50
ALOX15 P16050 1/20 0.50
TSHR P16473 1/20 0.50
CYP4F2 P78329 2/20 0.49
CYP4A11 Q02928 2/20 0.49
HTT P42858 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
PTGDR2 Q9Y5Y4 1/20 0.45
RAB9A P51151 2/20 0.43
CCR6 P51684 1/20 0.41
HKDC1 Q2TB90 1/20 0.41
KMT2A Q03164 2/20 0.41
TTBK1 Q5TCY1 1/20 0.40
TTBK2 Q6IQ55 1/20 0.40
CA12 O43570 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2893364 0.88 ALDH1A1 (0.65) ALDH1A1MAPTGAAHSD17B10KDM4E
SCHEMBL1754056 0.86 ALDH1A1 (0.46) ALDH1A1MAPTGAAHSD17B10KDM4E
SCHEMBL29775267 0.86 ALDH1A1 (0.46) ALDH1A1MAPTGAAHSD17B10KDM4E
SCHEMBL23033950 0.86 CA12 (0.51) ALDH1A1MAPTGAAHSD17B10KDM4E
SCHEMBL29943277 0.86 ALDH1A1 (0.53) ALDH1A1MAPTGAAHSD17B10KDM4E
SCHEMBL1022658 0.86 ALDH1A1 (0.53) ALDH1A1MAPTGAAHSD17B10KDM4E
SCHEMBL30966102 0.85 LOXL2 (0.54) ALDH1A1MAPTGAAHSD17B10KDM4E
SCHEMBL27433184 0.85 LOXL2 (0.54) ALDH1A1MAPTGAAHSD17B10KDM4E
SCHEMBL31385513 0.85 ALDH1A1 (0.49) ALDH1A1MAPTGAAHSD17B10KDM4E
SCHEMBL27434050 0.83 CYP4A11 (0.54) ALDH1A1MAPTGAAHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368123-A1 AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2024-11-07 US disclosed
WO-2024199069-A1 POLYARYL-CONTAINING MACROCYCLIC COMPOUND AND USE THEREOF 浙江养生堂天然药物研究所有限公司 2024-10-03 WO disclosed
WO-2024175082-A1 SALT CONTAINING AROMATIC RING DERIVATIVE ANTAGONIST, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 江苏豪森药业集团有限公司 2024-08-29 WO disclosed
EP-4393920-A1 AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2024-07-03 EP disclosed
EP-4393920-A1 AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2024-07-03 EP disclosed
US-20240207224-A1 MACROCYCLIC CHALCONE-AMIDE DERIVED ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2024-06-27 US disclosed
WO-2024107783-A2 NOVEL MACROCYCLIC CHALCONE-AMIDE DERIVED ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. (US) 2024-05-23 WO disclosed
CN-117886881-A Chimeric compound for targeted degradation of BCL-2 protein, preparation method and application thereof in medicine 江苏恒瑞医药股份有限公司 2024-04-16 CN disclosed
CN-117836294-A Biological antagonist containing aromatic ring, preparation method and application thereof 上海翰森生物医药科技有限公司 2024-04-05 CN disclosed
CN-111683951-B Triazolopyrimidine derivatives useful as ghrelin O-acyltransferase (GOAT) inhibitors 勃林格殷格翰国际有限公司 2023-10-13 CN disclosed
EP-2190811-A1 RENIN INHIBITORS Merck Frosst Canada Ltd. (CA) 2010-06-02 EP disclosed
WO-2009023964-A1 RENIN INHIBITORS MERCK FROSST CANADA LTD. (CA) 2009-02-26 WO disclosed
US-20080108638-A1 2-Sulfanyl-Benzoimidazol-1-Yl-Acetic Acid Derivatives as Crth2 Antagonists ACTELION PHARMACEUTICALS,LTD. (CH) 2008-05-08 US disclosed
EP-1784182-A1 2-SULFANYL-BENZIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2007-05-16 EP disclosed
US-7148250-B2 Indoles as NAALADase inhibitors GUILFORD PHARMACEUTICALS INC. (US) 2006-12-12 US disclosed
WO-2006021418-A1 2-SULFANYL-BENZOIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2006-03-02 WO disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
US-20050080128-A1 Indoles as naaladase inhibitors EISAI INC. 2005-04-14 US disclosed
WO-2005018557-A2 SUBSTITUTED PYRIDINONES PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed
WO-2003057670-A2 INDOLES AS NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 2003-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108638-A1 2-Sulfanyl-Benzoimidazol-1-Yl-Acetic Acid Derivatives as Crth2 Antagonists HRH2, HRH1, HRH3 ALDH1A1 470/4885MAPT 4293/4885GAA 3919/4885
US-20240207224-A1 MACROCYCLIC CHALCONE-AMIDE DERIVED ANTIVIRAL AGENTS ACE, ACE2, SARS1 ALDH1A1 3183/4885MAPT 3583/4885GAA 777/4885
US-20050080128-A1 Indoles as naaladase inhibitors NAALAD2, RIMKLA, NGF ALDH1A1 158/4885MAPT 150/4885GAA 87/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 ALDH1A1 741/4885MAPT 2543/4885GAA 2368/4885
US-20240368123-A1 AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF REN, BDKRB2, BDKRB1 ALDH1A1 2323/4885MAPT 4459/4885GAA 3158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.